BACKGROUND: Human failing heart due to idiopathic dilated cardiomyopathy is associated with decreased sarcoplasmic reticulum Ca(2+) uptake. However, it is unknown as to which mechanism leads to this abnormality. METHODS: Immunodetectable sarcoplasmic reticulum proteins (phospholamban [PLB], phosphorylated PLB at serine-16 or threonine-17, calsequestrin and Ca(2+)-ATPase levels), the activities of Ca(2+)-calmodulin-dependent protein kinase and protein phosphatase and Ca(2+) uptake at varying Ca(2+) concentrations were determined in left ventricular specimens from the same 7 failing hearts (ejection fraction 20 +/- 2%) due to idiopathic dilated cardiomyopathy and 5 non-failing explanted control donor hearts. RESULTS: In failing hearts, compared with control donors, decreased maximal velocity and affinity of Ca(2+) uptake for Ca(2+) were found to be associated with reduced expression levels of Ca(2+)-adenosine triphosphatase (ATPase), PLB and phosphorylated PLB at serine-16, but not of calsequestrin and phosphorylated PLB at threonine-17. In contrast, protein phosphatase activity increased significantly and the activity and protein expression level of the delta isoform of Ca(2+)-calmodulin-dependent protein kinase remained unchanged in failing hearts compared with control donors. CONCLUSIONS: The impaired maximal velocity of sarcoplasmic reticulum Ca(2+) uptake may be due in part to reduced protein expression level of Ca(2+)-ATPase, whereas the reduced affinity may be due in part to the reduced ratio of Ca(2+)-ATPase to PLB and reduced PLB phosphorylation at serine-16 in failing hearts. The latter abnormality may be due in part to increased protein phosphatase activity. These results suggest that selective enhancement of Ca(2+) uptake into the sarcoplasmic reticulum by pharmaceutical agents, or by molecular tools that inhibit phosphatase activity, would be a valuable therapeutic approach for treating, or at least retarding, the process of heart failure.
BACKGROUND:Human failing heart due to idiopathic dilated cardiomyopathy is associated with decreased sarcoplasmic reticulum Ca(2+) uptake. However, it is unknown as to which mechanism leads to this abnormality. METHODS: Immunodetectable sarcoplasmic reticulum proteins (phospholamban [PLB], phosphorylated PLB at serine-16 or threonine-17, calsequestrin and Ca(2+)-ATPase levels), the activities of Ca(2+)-calmodulin-dependent protein kinase and protein phosphatase and Ca(2+) uptake at varying Ca(2+) concentrations were determined in left ventricular specimens from the same 7 failing hearts (ejection fraction 20 +/- 2%) due to idiopathic dilated cardiomyopathy and 5 non-failing explanted control donor hearts. RESULTS: In failing hearts, compared with control donors, decreased maximal velocity and affinity of Ca(2+) uptake for Ca(2+) were found to be associated with reduced expression levels of Ca(2+)-adenosine triphosphatase (ATPase), PLB and phosphorylated PLB at serine-16, but not of calsequestrin and phosphorylated PLB at threonine-17. In contrast, protein phosphatase activity increased significantly and the activity and protein expression level of the delta isoform of Ca(2+)-calmodulin-dependent protein kinase remained unchanged in failing hearts compared with control donors. CONCLUSIONS: The impaired maximal velocity of sarcoplasmic reticulum Ca(2+) uptake may be due in part to reduced protein expression level of Ca(2+)-ATPase, whereas the reduced affinity may be due in part to the reduced ratio of Ca(2+)-ATPase to PLB and reduced PLB phosphorylation at serine-16 in failing hearts. The latter abnormality may be due in part to increased protein phosphatase activity. These results suggest that selective enhancement of Ca(2+) uptake into the sarcoplasmic reticulum by pharmaceutical agents, or by molecular tools that inhibit phosphatase activity, would be a valuable therapeutic approach for treating, or at least retarding, the process of heart failure.
Authors: R John Solaro; David M Montgomery; Lynn Wang; Eileen M Burkart; Yunbo Ke; Susan Vahebi; Peter Buttrick Journal: J Nucl Cardiol Date: 2002 Sep-Oct Impact factor: 5.952
Authors: Thorsten Krause; Stefanie Grote-Wessels; Felix Balzer; Peter Boknik; Ulrich Gergs; Uwe Kirchhefer; Igor B Buchwalow; Frank U Müller; Wilhelm Schmitz; Joachim Neumann Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2018-05-24 Impact factor: 3.000
Authors: Sean T DeGrande; Sean C Little; Derek J Nixon; Patrick Wright; Jedidiah Snyder; Wen Dun; Nathaniel Murphy; Ahmet Kilic; Robert Higgins; Philip F Binkley; Penelope A Boyden; Cynthia A Carnes; Mark E Anderson; Thomas J Hund; Peter J Mohler Journal: J Biol Chem Date: 2012-11-30 Impact factor: 5.157
Authors: John Paul Glaves; Joseph O Primeau; Przemek A Gorski; L Michel Espinoza-Fonseca; M Joanne Lemieux; Howard S Young Journal: Biophys J Date: 2019-11-28 Impact factor: 4.033
Authors: Nicole Brüchert; Nirmala Mavila; Peter Boknik; Hideo A Baba; Larissa Fabritz; Ulrich Gergs; Uwe Kirchhefer; Paulus Kirchhof; Marek Matus; Wilhelm Schmitz; Anna A DePaoli-Roach; Joachim Neumann Journal: Am J Physiol Heart Circ Physiol Date: 2008-08-08 Impact factor: 4.733